Correlation Between Madrigal Pharmaceuticals and Mersana Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and Mersana Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and Mersana Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Madrigal Pharmaceuticals and Mersana Therapeutics, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and Mersana Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of Mersana Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and Mersana Therapeutics.

Diversification Opportunities for Madrigal Pharmaceuticals and Mersana Therapeutics

-0.21
  Correlation Coefficient

Very good diversification

The 3 months correlation between Madrigal and Mersana is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and Mersana Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mersana Therapeutics and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with Mersana Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mersana Therapeutics has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and Mersana Therapeutics go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and Mersana Therapeutics

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 0.49 times more return on investment than Mersana Therapeutics. However, Madrigal Pharmaceuticals is 2.06 times less risky than Mersana Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Mersana Therapeutics is currently generating about -0.19 per unit of risk. If you would invest  31,087  in Madrigal Pharmaceuticals on December 21, 2024 and sell it today you would earn a total of  2,426  from holding Madrigal Pharmaceuticals or generate 7.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Madrigal Pharmaceuticals  vs.  Mersana Therapeutics

 Performance 
       Timeline  
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Mersana Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Mersana Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Madrigal Pharmaceuticals and Mersana Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Madrigal Pharmaceuticals and Mersana Therapeutics

The main advantage of trading using opposite Madrigal Pharmaceuticals and Mersana Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, Mersana Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will offset losses from the drop in Mersana Therapeutics' long position.
The idea behind Madrigal Pharmaceuticals and Mersana Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance